TuHURA Biosciences remains a high-risk investment due to severe cash constraints and imminent dilution risk despite progress in its immunotherapy pipeline. HURA's phase 3 trial for IFx-Hu2.0 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback